New mutation in parE in a pneumococcal in vitro mutant resistant to fluoroquinolones

Antimicrob Agents Chemother. 2001 Mar;45(3):952-5. doi: 10.1128/AAC.45.3.952-955.2001.

Abstract

For an in vitro mutant of Streptococcus pneumoniae selected on moxifloxacin four- to eightfold-increased MICs of new fluoroquinolones, only a twofold-increased MIC of ciprofloxacin, and a twofold-decreased MIC of novobiocin were observed. This phenotype was conferred by two mutations: Ser81Phe in GyrA and a novel undescribed His103Tyr mutation in ParE, outside the quinolone resistance-determining region, in the putative ATP-binding site of topoisomerase IV.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine Triphosphate / metabolism
  • Amino Acid Sequence
  • Anti-Infective Agents / pharmacology*
  • Bacterial Proteins / genetics*
  • Binding Sites
  • DNA Topoisomerase IV
  • DNA Topoisomerases, Type II / metabolism
  • DNA-Binding Proteins / genetics*
  • Drug Resistance, Microbial / genetics
  • Fluoroquinolones
  • Humans
  • Microbial Sensitivity Tests
  • Molecular Sequence Data
  • Mutation
  • Phenotype
  • Pneumococcal Infections / microbiology
  • Sequence Homology, Amino Acid
  • Streptococcus pneumoniae / drug effects*
  • Streptococcus pneumoniae / genetics

Substances

  • Anti-Infective Agents
  • Bacterial Proteins
  • DNA-Binding Proteins
  • Fluoroquinolones
  • Adenosine Triphosphate
  • DNA Topoisomerase IV
  • DNA Topoisomerases, Type II